comparemela.com

Page 3 - Kausikk Ray News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New dietary recommendations, dyslipidemia guidelines and more to be featured at NLA 2023

The National Lipid Association Scientific Sessions will be held today to Sunday and will spotlight statements on nutrition in adults with dyslipidemia, include sessions on the integration of lipid guidelines in clinical practice and more.Healio | Cardiology Today spoke with NLA President Kevin C. Maki, PhD, CLS, FNLA, FTOS, FACN, chief scientist at Midwest Biomedical Research and adjunct

United statesNorth seaOceans generalAntonioj vallejo vazZahid ahmadRoberts rosensonEli lillyPeter libbyKevinc makiKausikk rayPresidentkevinc makiMayas safarovaMphil cantabShireen khouryDaniele sofferByscott buzby

UK s NICE Recommends Lower-Risk Thresholds for Statin Therapy

Treating younger patients with a 10-year risk less than 10% is more likely to prevent CVD before it’s too late, experts said.

United kingdomPaul chrispDarrel francisKausikk rayNational institute of healthEuropean atherosclerosis societyCentre for guidelinesMd imperial college londonNational instituteCare excellenceImperial college londonLike francisCholesterol treatment trialist

Evolocumab s LDL Lowering Surpassed Inclisiran s in ORION-3

Results from a crossover subgroup of 92 patients in ORION-3 documented evolocumab s greater LDL-lowering efficacy compared with inclisiran.

United statesNew yorkCity ofUnited kingdomKausikk rayRoberts rosensonAmerican heart associationMedicines companyAmerican college of cardiologyDrug administrationImperial college londonIcahn school of medicine at mount sinaiLancet diabetesIcahn schoolMount sinaiAmerican college

Sustained LDL-Cholesterol Reductions With Inclisiran: ORION-3

LDL-C stayed down for 4 years and so did PCSK9 levels, but the real test for inclisiran will be the ongoing CV outcomes studies.

United statesBaylor college of medicineVijay nambiSanofi regeneronKausikk rayMd baylor college of medicineDrug administrationEuropeans medicines agencyMd imperial college londonImperial college londonBaylor college

NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia

New post-hoc data accepted as late breaking abstracts at the 90th European Atherosclerosis Society (EAS) Congress and 2022 National Lipid Association (NLA) Scientific Sessions NewAmsterdam Pharma

United statesCity ofUnited kingdomNorth lanarkshireNewamsterdam pharmaHannah deresiewiczKausikk rayCarmen lopezKostenloser wertpapierhandelMichael davidsonJohn kasteleinProfessor of public healthImperial college londonImperial centre for cardiovascular disease preventionNational lipid associationEuropean atherosclerosis society

vimarsana © 2020. All Rights Reserved.